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ORIGINAL ARTICLE
INTRODUCTION
Cyclooxygenase is a key enzyme in prostaglandin
biosynthesis.1 Two isoform of COX has been recognized.
COX-1 is a constitutively expressed enzyme in many
tissues, including the gastrointestinal tract,2,3 while
COX-2 which is normally undetectable in most tissues,
is induced in response to a number of stimuli including
the cytokines interleukine-1 (IL-1), interferon-γ
(INF-γ), tumor necrosis factor (TNF)4 and activation of
epidermal factor receptor (EGF-r).5
Expression of COX-2 had been reported in colorectal
cancers,6,7 pancreatic cancer,8 hepatocellular
carcinoma,9,10 esophageal cancers11,12 and gastric
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ABSTRACT
Background: Expression of COX-2 in vitro has been shown to have a number of cellular effects including
increasing proliferation, reducing apoptosis promoting angiogenesis, decreasing E-cadherin expression and
increasing invasive/metastatic potential.
Aims: To determine the role of COX-2 in the development and metastasis potential of gastric carcinoma in
human subjects.
Methods: Tissue samples were obtained from surgically removed specimens of 48 patients with primary
gastric adenocarcinoma who underwent gastrectomy from January 1998 to December 1999. The specimens
were stained for HE while COX-2 expressions in cancer fold and antrum site were evaluated
immunohistochemically. Expression of COX-2 was defined as positive when either one of cancer lesion or
antrum site showed immunoreactivity.
Results: Preliminary result from 12 out of 48 cases, COX-2 immunoreactivity was detected in 50%
(6 of 12 specimens). Expression of COX-2 were more frequent in tumor with serosal invasion (5 of 6
specimens), lymph node metastases (3 of 3 specimens), tumor size more than 4 cm and were significant,
statistically (p<0.05). The expression of COX-2 in well differential carcinoma type was similar with in poorly
differentiated carcinoma type.
Conclusion: COX-2 expression in gastric carcinoma tissue is correlated closely with tumor size, serosal
invasion and lymph node metastases, indicating that COX-2 is involved in the growth and metastases of
gastric carcinoma.
Keywords: Gastric carcinoma, cyclooxygenase-2, invasion, immunochemistry
cancer.13,14 COX-2 expression is especially prominent
in gastrointestinal cancers, suggesting its important role
in gastrointestinal cancers.6,7,11,15
Over expression of COX-2 in vitro has been shown
to have a number of cellular effects including increasing
proliferation, reducing apoptosis16 promoting
angiogenesis,17,18 decreasing E-cadherin expression16 and
increasing invasive/metastatic potential.19
Recent studies have been demonstrated that COX-2
could affect carcinogenesis via several mechanisms.
COX-2 mediated PG biosynthesis has been suggested to
be involved in the development of cancers based on
elevated level of PGs, especially PGE2, in cancer
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tissues.20-22
In papilomas and carcinomas in mouse skin,
overexpression of COX-2 is associated with large
increase in PGE2 and PGF2α.23  COX-2 is detected in
majority of colon tumor samples6 and is involved in early
events of colon carcinogenesis.24,25 However the
association between COX-2 and the metastatic
potential of stomach carcinoma in human has been not
yet studied. We investigated the involvement of  COX-2
in the development and metastasis of human gastric
carcinoma.
MATERIALS AND METHODS
Patients and Samples
Tissue samples were obtained from surgically
removed specimens of 48 patients with primary gastric
adenocarcinoma who underwent gastrectomy from
January 1998 to December 1999 at Yamanashi
University/Hospital, Japan. Patients with multiple organ
malignancy have been excluded from this series. The
surgical specimens were fixed in 10% buffered
formaldehyde, embedded in paraffin, sectioned and
stained with H & E. Specimens from antrum; outside of
cancer lesion were also obtained from the same patients.
These specimens were subjected to detailed
pathological examination, which identified severity of
gastritis, depth of invasion, nodal status, marginal
involvement and histological type of the tumors.
The  clinicopathologic data were analyzed according to
the Japanese classification system for gastric carcinoma
outlined by the Japanese Gastric Cancer Association.26
Well differentiated gastric carcinoma (WGC) included
papillary and tubular adenocarcinoma, poorly
differentiated medullary carcinoma and well
differentiated mucinous carcinoma; whereas poorly
differentiated gastric carcinoma (PGC) included poorly
differentiated scirrhous carcinoma, signet ring cell
carcinoma and poorly differentiated mucinous
carcinoma.27 Gastritis pattern in the antrum site was
determined according to Update Sydney System.
Immunohistochemical Staining
Paraffin-embedded blocks were sectioned at about
5 mm thickness, deparaffinized and rehydrated. Slides
were immersed in methanol and 30% hydrogen
peroxide for 15 minutes to block the endogenous
peroxidase activity. After rinsing with PBS the
specimens were immersed in normal goat serum for 30
minutes. After rinsing three times with PBS in
20 minutes, slides were incubated overnight in room
temperature with the polyclonal antibody against
COX-2 (Nichirei, Tokyo, Japan) in a dilution of 1:100.
All the slides were rinsed with PBS three times in 20
minutes and incubated with an avidin biotin conjugated
anti Rabbit IgG (Nichirei, Tokyo, Japan) for 2 hours. After
rinsing the slides were incubated with peroxidase-
conjugated streptavidin (Nichirei, Tokyo, Japan) for
another two hours and followed by DAB staining
(Histofine Kit; Nichirei, Tokyo, Japan).
A senior morphologist examined the immuno-
histochemical expression of COX-2. Expression of
COX-2 was defined as positive when either one of
cancer lesion or antrum site from the same patient showed
immunoreactivity. The expression of COX-2
immuno-reactivity was graded semi quantitatively and
each sample was assigned of the following categories:
negative (-), small (+), moderate (++) and many (+++).
The intensity of immunostaining was determined as 0
(negative), 1 (weak), 2 (intermediate) and 3 (strong).
The immunoreactive score was calculated by
multiplication of the grade of positive cells and the
staining intensity.
Statistical Analysis
The score of COX-2 expression was compared within
pathological parameters such as: histopathological type,
stage grouping, venous vessel invasion and lymphatic
vessel invasion in gastric wall, serosal invasion and the
presence of lymph node metastasis using Mann-Whitney
U test.
RESULTS
Preliminary result from 12 out of 48 cases was
demonstrated in Table 1. COX-2 immunoreactivity was
detected in 50% cases (6 of 12 specimens). The score
of COX-2 expressions were related to the tumor size
more than 4 cm, serosal invasion and lymph node
metastasis (p<0.05). The score of COX-2 expression
showed no correlation with histopathologic type,
lymphatic and vascular permeation, UICC TNM stage,
the presence of Helicobacter pylori, gastric atrophy,
intestinal metaplasia and gastritis score (p>0.05).
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Figure 1. Immunopositive cells in the antrum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunopositive cells in the cancer fold  
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Table 1. Characteristic of 12 Gastric Carcinoma Cases and COX-2 Expression 
Case Age/ sex G pT Ser pN 
Size 
(cm) 
Stage 
Group v Ly IM Atrophy Hp COX-2 
1 48/M 1 3 1 0 3.75 III a - ve + ve 2 1 + ve No 
2 49/M 1 1 0 0 1.50 I a - ve - ve 2 2 + ve No 
3 51/M 2 2 0 0 1.25 I b - ve - ve 2 2 + ve No 
4 65/F 2 0 0 0 2.30 I a - ve - ve 2 2 + ve No 
5 48/M 2 1 0 0 1.50 I a - ve - ve 0 1 - ve No 
6 59/M 1 2 0 0 3.75 I b - ve - ve 2 2 + ve No 
7 64/M 1 0 0 0 2.50 1a - ve - ve 2 1 + ve Yes 
8 71/M 1 4 1 1 5.30 III b - ve - ve 2 2 + ve Yes 
9 67/M 2 4 1 1 12.25 IV b +ve + ve 2 2 + ve Yes 
10 68/M 1 4 1 0 6.75 II - ve + ve 0 1 - ve Yes 
11 69/M 2 3 1 1 2.75 II + ve + ve 2 1 - ve Yes 
12 55/M 2 3 1 0 7.50 III a - ve - ve 0 1 - ve Yes 
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DISCUSSION
The present study demonstrated the involvement of
COX-2 in gastric carcinoma. Recently Ohno et al,28
reported that the degree of COX-2 mRNA elevation was
related to the depth of primary tumor invasion. Similar
findings also reported by Murata et al,29 that carcinoma
tissue expressed remarkably higher levels of COX-2 in
advanced carcinoma compare to early gastric
carcinoma. Present study revealed the expression of
COX-2 related to the serosal invasion but not to stage of
diseases (stage I and II vs. stage III and IV, p>0.05) in
gastric carcinoma patients. Both of these factors were
claimed to be a prognostic factors.27
Recent studies have found a correlation between the
levels of COX-2 expression and lymph node metastasis
and lymphatic permeation in patients with gastric
carcinoma. Murata et al,29 found that tumor over
expression of COX-2 protein, according to Western blot
analysis, was associated significantly with invasion into
gastric wall lymphatic vessels as well as with metastasis
to lymph node. Yamamoto et al, also reported that over
expression of COX-2 protein was associated significantly
with lymphatic involvement and lymphatic metastasis.
On the contrary Ohno et al,28 using RT-PCR analysis
reported that the correlation between the levels of
COX-2 mRNA and lymph node metastasis were not
significant. Present study showed COX-2 expression
were associated to lymph node metastasis, but did not
attain a significant association with lymphatic permeation
in gastric carcinoma patients.
The size of tumor more than 4 cm has been proposed
as an independent prognostic factor previously.27
Interestingly, our result revealed the expression of
COX-2 was related to the size of tumor more than 4 cm.
In the human stomach, Helicobacter pylori infection
is associated with chronic gastritis and leads to mucosal
atrophy and intestinal metaplasia, whish are
pre-cancerous lesion. Furthermore, Helicobacter pylori
infection is associated with a Ca-fold increased risk of
gastric carcinoma.30 Sung et al,31 reported that COX-2
protein is expressed in the gastric epithelium throughout
the multistep gastric carcinogenesis cascade. The present
study failed to demonstrated any association between
the expression of COX-2 and the presence of
Helicobacter pylori, gastric atrophy, intestinal
metaplasia and the severity of gastritis.
CONCLUSION
COX-2 expression in gastric carcinoma tissue is
correlated closely with tumor size, serosal invasion and
lymph node metastases, indicating that COX-2 is involved
in the growth and metastasis of gastric carcinoma.
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